CGON
Price
$67.71
Change
+$3.65 (+5.70%)
Updated
Nov 4 closing price
Capitalization
6B
9 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$32.36
Change
+$1.03 (+3.29%)
Updated
Nov 4 closing price
Capitalization
3.12B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGON vs IDYA

CGON vs IDYA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CGON vs. IDYA commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a Buy and IDYA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CGON with price predictions
Nov 03, 2026

CGON in +3.90% Uptrend, rising for three consecutive days on October 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CGON advanced for three days, in 118 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CGON's RSI Oscillator exited the oversold zone, 9 of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 39 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 21 of 29 cases over the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 39 cases where CGON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

The Aroon Indicator for CGON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.832) is normal, around the industry mean (3.051). P/E Ratio (-25.171) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for IDYA with price predictions
Nov 03, 2026

IDYA's Indicator enters downward trend

The Aroon Indicator for IDYA entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator formed such a pattern. In 201 of the 241 cases the stock moved lower. This puts the odds of a downward move at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 83 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for IDYA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 32 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for IDYA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 218 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.604) is normal, around the industry mean (3.051). P/E Ratio (-16.854) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
PROFIT vs RISK RATING
1..100
87
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
31
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGONIDYA
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 8 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (CGON: $64.06 vs. IDYA: $31.33)
Brand notoriety: CGON and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 75% vs. IDYA: 242%
Market capitalization -- CGON: $5.68B vs. IDYA: $3.12B
CGON [@Biotechnology] is valued at $5.68B. IDYA’s [@Biotechnology] market capitalization is $3.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 1 FA rating(s) are green while IDYA’s FA Score has 2 green FA rating(s).

  • CGON’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 2 green, 3 red.
According to our system of comparison, both CGON and IDYA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • CGON’s TA Score: 4 bullish, 3 bearish.
  • IDYA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CGON is a better buy in the short-term than IDYA.

Price Growth

CGON (@Biotechnology) experienced а +1.78% price change this week, while IDYA (@Biotechnology) price change was -6.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.61%. For the same industry, the average monthly price growth was -11.21%, and the average quarterly price growth was -16.43%.

Reported Earning Dates

CGON is expected to report earnings on Nov 13, 2026.

IDYA is expected to report earnings on Feb 23, 2027.

Industries' Descriptions

@Biotechnology (-3.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
+3.39%
MLTX - CGON
49%
Loosely correlated
+2.01%
IDYA - CGON
43%
Loosely correlated
-0.98%
SRRK - CGON
43%
Loosely correlated
+2.49%
ORKA - CGON
41%
Loosely correlated
+4.32%
LXEO - CGON
40%
Loosely correlated
+1.63%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AAOG0.700.03
+4.51%
Leverage Shares 2X Long AAOI Daily ETF (AAOG)
IDNA42.470.77
+1.85%
iShares Genomics Immunology and Healthcare ETF (IDNA)
ZSB20.59N/A
N/A
USCF Sustainable Battery Metals Strategy Fund (ZSB)
JSI49.99-0.01
-0.02%
Janus Henderson Securitized Income ETF (JSI)
FLEE38.09-0.29
-0.75%
Franklin FTSE Europe ETF (FLEE)